<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627261</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL15_0316</org_study_id>
    <nct_id>NCT02627261</nct_id>
  </id_info>
  <brief_title>Multiple Myeloma Minimal Residual Disease</brief_title>
  <acronym>MMRD</acronym>
  <official_title>Comparison of Three Methods to Evaluate Residual Disease in Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three methods including flow cytometry, next generation sequencing and determination of
      circulating tumor cells will be performed at different time points in patients with
      previously undiagnosed multiple myeloma in order to determine the most sensitive method to
      detect residual disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of residual disease</measure>
    <time_frame>Residual disease is assessed up to 18 months after inclusion</time_frame>
    <description>study the sensitivity of the method of quantification of circulating tumor cells compared to 2 others methods of detection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>kinetic of variation of the residual tumor cells detected by flow cytometry method</measure>
    <time_frame>18 months</time_frame>
    <description>% positive cells in bone marrow sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kinetic of variation of the residual tumor cells detected by new generation sequencing method</measure>
    <time_frame>18 months</time_frame>
    <description>% positive in bone marrow sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kinetic of variation of the circulating tumor cells</measure>
    <time_frame>18 months</time_frame>
    <description>number of cells / mL of blood</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>patients with multiple myeloma</arm_group_label>
    <description>blood samples and bone marrow aspirates will be collected in patients at different time point</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples and bone marrow aspirates will be collected</intervention_name>
    <description>Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)</description>
    <arm_group_label>patients with multiple myeloma</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      a gene sequencing technology will be used on bone marrow samples to detect residual disease
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will focus on adult patients with multiple myeloma and who will receive a
        treatment with high-dose melphalan and autologous bone marrow transplantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years

          -  previously undiagnosed myeloma

          -  eligible for high dose therapy and bone marrow transplantation

          -  signed consent

        Exclusion Criteria:

          -  ongoing therapy for another neoplasia

          -  Patients with other hematologic malignancies,

          -  patients deprived of liberty for administrative or judicial reasons

          -  previously treated for myeloma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles DUMONTET, PU-PH</last_name>
    <phone>+33 4 78 86 41 28</phone>
    <email>charles.dumontet@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mina EDDAHBI</last_name>
    <phone>+33 4 78 77 12 02</phone>
    <email>mina.eddahbi@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Facon Thierry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Hôtel-Dieu de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Moreau Philippe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénité</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles DUMONTET, PU-PH</last_name>
      <email>charles.dumontet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel KARLIN, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie DUCASTELLE LEPRETRE, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>residual disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

